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Abstract:
The medicinal activity of COX-2 inhibitors are sufficiently beneficial to urge the search
for new drug designs. This study presents 16 analogs of lumiracoxib and 10 analogs to
valdecoxib having properties suitable as COX-2 inhibitors. For lumiracoxib analogs the
mean Log P, polar surface area, and formula weight are 3.00, 70.46 A2 , and 276.60,
respectively. For valdecoxib analogs the mean Log P, polar surface area, and formula
weight are 3.65, 68.46 A2 , and 322.32, respectively. Grubb’s test analysis of seven
properties for seven known COX-2 selective inhibitors and those of 26 analog
compounds indicated no outliers. The unpaired t-test compared Log P and polar surface
area of seven known COX-2 inhibitors to all 26 analogs and found no difference. All 26
analogs showed no violation of the Rule of 5, this being an indicator of favorable
bioavailability. Hierarchical cluster analysis by single linkage indicated lumiracoxib is
most similar to analogs 2, 4, 5, 6, 7, 9, 10, 11, 14, 15, 16, and 17. Valdecoxib has
highest similarity to analogs 8, 19, 21, 22, 23, 26, 27, and 28. Multiple regression
analysis successfully produced equations for prediction of similar compounds to
lumiracoxib and valdecoxib. Path analysis indicated that number of atoms, oxygen &
nitrogen atoms, and Log P are the greatest determinants for formula weight for known
COX-2 inhibitors. Criteria for molecular properties is established for identifying COX-2
inhibitors. These 26 analogs show much potential for active COX-2 inhibition.
Keywords:
Anti-inflammatory, COX-2, cyclooxygenase, lumiracoxib, pattern recognition,
valdecoxib.

INTRODUCTION
Non-steroidal anti-inflammatory drugs (NSAIDs) are a group of drugs that provide
analgesic (pain reducer), antipyretic (fever-reducing), and anti- inflammatory effects [1].
Clinical application of NSAIDs include the following: rheumatoid arthritis, osteoarthritis,
gout, headache (migrane), pain due to inflammation and tissue injury, pyrexia,
postoperative pain, pain associated with Parkinson’s disease, and dysmenorrhea [1].

Selective COX-2 (cyclooxy- genase-II enzyme) inhibitors avoid the complications and
potentially fatal bleeding within the gastrointestinal track induced by COX-1 inhibitors [26].
Although the trial data varies substantially among COX-2 selective inhibitors on
myocardial infarction (MI) events, an increased risk of MI exists shown in evidence
based on patient-year exposure [7,8]. Desired beneficial medicinal activity maintains the
strong interest in COX-2 selective inhibitors. A single daily dose of celecoxib has been
shown to significantly reduce the occurrence of colorectal adenomas [9,10], and could
be effective in preventing cutaneous squamous cell carcinomas and basal cell
carcinomas in high risk individuals [11]. Studies focusing on the role of COX-2 in the
tumorigenesis of breast cancer have strongly hinted to the potential of COX-2 specific
inhibitors to prevent and treat breast cancer [12,13]. Likewise studies have suggested a
similar application of COX-2 selective inhibitors for prostate cancer [14].
Previous studies have shown that inhibition of COX-2 enzyme will induce useful
therapeutic effects on solid tumors and deter tumor cell growth [15].
Essentially the reduction of the activity of COX-2 enzyme or protein expression could
inhibit cancer cell growth and NSAIDs can be employed for chemoprevention of cancer
[16,17]. Use of COX-2 selective inhibitors parallel a doxorubicin regimen will inhibit
growth of hepatocellular carcinoma cells which is the fourth leading cause of cancer
related mortality worldwide [15]. However the available data clearly extends a
cautionary flag concerning the risk of cardiovascular events or stroke with administration
of COX-2 selective inhibitors [18-20].
Nevertheless the considerable potential benefits of COX2 selective inhibitors strongly
supports the continued study and development of new drug designs. This study
presents 26 drug structures analogous to known COX-2 selective inhibitors and
possessing properties associated with successful drugs.

MATERIALS AND METHODS
Properties and Molecular Modeling
Numerical values of molecular properties and description of drug structures were
accomplished by utilizing Molinspiration (Molinspiration Cheminformatics, Nova ulica 61,
SK900 26 Slovensky Grob, Slovak Republic). In silico search for drug structures
analogous to lumiracoxib was accomplished by Molinspiration ‘search by similarity’ with
a success rate of less than 16% (Molinspiration Cheminformatics, Nova ulica 61, SK900 26 Slovensky Grob, Slovak Republic, http://www.molinspiration.com/). In silico
search for drug structures analogous to valdecoxib was accomplished by Molinspiration
‘search by similarity’ with a success rate of less than 10%. Additional elucidation of
structure components was enhanced and enabled by utilizing ACD ChemSketch
Modeling v. 12.01 (Advanced Chemistry Development, 110 Yonge Street, Toronto
Ontario, M5C 1T4 Canada, http://www.molinspiration.com/services/search.html).

Determination of drug-likeness scores for kinase inhibitor, protease inhibitor, and
enzyme inhibitor was determined by Molinspiration Cheminformatics (http://www.
molinspiration.com/cgi-bin/properties).
Pattern Recognition and Multivariate Statistical Analysis
To identify underlying associations and patterns within the numerical properties required
the use of various pattern recognition techniques. Included in these analyses are
hierarchical cluster analysis accomplished by KyPlot v. 2.0 Beta 15 (copyright Koichi
Yoshioka 1997-2001). In addition, analysis of non-hierarchical K-means cluster
analysis, oneway ANOVA, Kruskal-Wallis test, Mann-Whitney U Test, and 95% ellipses
were performed by PAST v. 2.06 (copyright Oyvind Hammer, D.A.T. Harper 19992008). Path Analysis (the determination of path coefficients) was done by OpenStat
statistics package (copyright W.G. Miller, November 2010;
http://openstat.software.informer.com/).

Fig. (1). Structures of drug analogs to lumiracoxib. Characteristic common to all drugs are: 1) Two
aromatic rings; 2) At least two oxygen atoms; 3) At least one carboxyl group. Other atoms present but not
universal are halogen atoms, nitrogen atoms, and amide groups.

Various Statistical Analysis Data
Statistical analysis of numerical data including Pearson r correlation and descriptive
statistics were accomplished by Microsoft EXCEL v. 14.0.6112.5000 (EXCEL
Professional plus 2010). Multiple regression analysis of molecular property values was
accomplished by GraphPad Instat version 3.00 (GraphPad Software, Inc., San Diego
California USA; www.graphpad.com). Determination of numerical outliers was done by
Grubb’s test (extreme studentized deviate), and t test to compare two means was done
by (http://www.graphpad.com/quickcalcs/).

RESULTS
Utilizing lumiracoxib as the parent structure for an in silico search for similarity of
scaffolding and substituents did identify a set of 16 analogs. The search utilized an insitu library scrutiny and produced many structures. The count of suitable structures
actually produced from the total number of generated compounds was less than 16% of
the total. Shown in (Fig. 1), in addition to the parent compound lumiracoxib (drug 1), are
16 analogs that are examined for suitability as potential COX-2 selective inhibitors.
Structures of drug analogs to lumiracoxib. Characteristic common to these analogs are:
1) Two aromatic rings; 2) At least two oxygen atoms; 3) At least one carboxyl group; 4)
At least one –OH or –NHn group. Other atoms present but not universal are halogen
atoms, nitrogen atoms, methoxy groups, alkene groups, and amide groups.
Utilizing valdecoxib as the parent structure for in silico search for similarity in scaffolding
and substituents a set of 10 analogs were identified. The search by in situ library survey
and scrutiny identified various complex structures. The number of suitable structures
actually produced of the total number of generated compounds was less than 10% of
the total. Shown in (Fig. 2), in addition to the parent compound valdecoxib (drug 1), are
10 analogs that are examined for suitability as potential COX-2 inhibitors. Structures of
drug analogs to valdecoxib (sulfonamide based) have characteristic common to all: 1)
Two aromatic rings; 2) At least two oxygen atoms; 3) One sulfonamide group; 4) At
least one nitrogen atom. Other atoms present but not universal are chlorine atom,
oxadiazole substituent, and benzimidazole groups.
Previous studies have determined and compared the properties of established COX-2
selective inhibitors [21]. Those results, inclusive of lumiracoxib and valdecoxib, are
presented in Table 1 with statistical analysis shown in Table 2. Properties included are
Log P, polar surface area (PSA), formula weight (FW), molecular volume (MV), etc,
which will be analyzed to show that analog compounds in (Figs. 1 and 2) have the
capacity to be COX-2 inhibitors. The mean values for properties of known selective
COX-2 inhibitors (see summary statistics in Table 2) for Log P, PSA, FW, number of
atoms, and MV are 2.939, 70.41 A2 , 338.5, 23, and 282.7, respectively. The respective
properties determined for lumiracoxib analogous compounds are compiled in Table 3,
inclusive of Log P, PSA, FW, etc. These properties will be the focus of statistical and
pattern recognition analysis to prove their potential as COX-2 inhibitors. Likewise the

respective properties determined for valdecoxib analogous compounds are compiled in
Table 4, inclusive of Log P, PSA, FW, etc. Pearson r determinations for Table 3 and
Table 4 showed that a strong positive correlation occurs (r = 0.5298) between Log P
and number of atoms with a strong positive correlation (r = 0.6342) between Log P and
formula weight. In addition, a very strong positive correlation occurs (r = 0.7047)
between polar surface area and total oxygen and nitrogen atoms.

Fig. (2). Structures of drug analogs to valdecoxib. Characteristic common to all drugs are: 1) Two
aromatic rings; 2) At least two oxygen atoms; 3) At least one sulfonamide group. Other structure present
but not universal are chlorine atom, oxadiazole, and benzimidazole group.

The summary statistics for lumiracoxib based analogs (see Fig. 1) are presented in
Table 5. These determinations will be compared to findings for known selective COX-2
inhibitors presented in Table 2. Likewise the summary statistics for all valdecoxib based
analogs (see Fig. 2) are presented in Table 6. These determinations will be compared
to numerical values for known COX-2 selective inhibitors presented in Table 2. The
mean values of Log P, PSA, FW, number of atoms, and molecular volume shown in
Table 2 (known COX-2 selective inhibitors) is shown to have no significant difference
from mean values of the same properties for both lumiracoxib (Table 5) and valdecoxib
(Table 6) analogs.
Analysis of variance (ANOVA) is a general method to test for significant differences
between class means and enables all classes to be compared with each other
simultaneously and not individually [22]. The one-way analysis of variance is used to
test the claim that two or more population means are equal [22]. One-way ANOVA was
applied to test that Log P, polar surface area, and number of rotatable bonds of seven
known specific COX-2 inhibitors from Table 1 to the same properties of 26 analogs
found in Table 3 and Table 4. The results showed the means of the three molecular
properties (e.g. Log P, polar surface area, rotatable bonds) for 7 known specific COX-2
inhibitors and 26 analog compounds to be the same at P > 0.05 (P = 0.09866, P =
0.925, P = 0.2202, respectively).
Using the Kruskal-Wallis Test, we can decide whether the population distributions are
identical [22]. If P >0.05 then accept the null hypothesis that two or more populations
originate from the identical distributions. Again the KruskalWallis test shows polar
surface area and Log P of seven known selective COX-2 inhibitors of Table 1 to the
same properties of 26 analogs shown in Table 3 and Table 4 are in identical
distributions, P > 0.05 (P = 0.989, P = 0.1718, respectively).
Grubbs' test (or extreme studentized deviate test) is a statistical test used to detect
numerical outliers [22]. Comparing known COX-2 inhibitors of Table 1 to all analogs of
Tables 3 and 4 by Grubb’s test showed no outliers in the following properties: polar
surface area, number of atoms, molecular weight, number of rotatable bonds, number of
oxygen or nitrogen or hydroxyl or amine groups, and molecular volume.
The unpaired t-test compares the means of two groups and can be used to decide if the
averages of two samples are significantly different. If the P value is large, the data do
not give you any reason to conclude that the overall means differ [22]. Again when
applied to polar surface area and Log P for seven COX-2 inhibitors of Table 1 to all
analogs of Tables 3 and 4 the P = 0.8805 and P = 0.3543 (i.e. P > 0.05) so no
difference exists among the means of these drugs for properties tested.
Path analysis is used to describe the directed dependencies among a set of variables
and is used for testing cause and effect with the aim to give estimates of the magnitude
and significance of hypothesized causal connections between sets of variables [23,24].
Path Analysis for the formation of formula weight showed path coefficients (PC) for

descriptors Log P (PC = 0.824), number of atoms (PC = 2.024), number of oxygens &
nitrogens (PC = 1.616), and rotatable bonds (PC = -0.397). This suggests that number
of oxygen, nitrogen, and total number of atoms, as well as Log P important as well,
plays the most prominent role in formula weight of drugs (rotatable bonds are nominal
or extraneous).

Pattern recognition by cluster analysis (or clustering) has the goal of grouping a set of
objects in such a way that objects in the same cluster or group are most similar to each
other than to those in other clusters [23,24]. For obtaining a comparison of all analogs
the molecular properties in Table 3 and Table 4 are combined, these include: Log P,
polar surface area, number of atoms, number of oxygen-nitrogenhydroxide-amine
groups, and formula weight. Hierarchical cluster analysis using Euclidean distance and
single linkage was completed to resolve the 28 drugs into clusters of drugs having
highest similarity (see Fig. 3). The dendrogram shown in (Fig. 3), inclusive of all
compounds of (Figs. 1 and 2), clearly defines the 28 drugs as to the closest member
based on molecular properties. Drug 1 (lumiracoxib) is bound to node B and within
supercluster having 1, 10, 16, 14, 15, 5, 7, 11, 4, 17, 9, 13, 6, and 2. Drug 18
(valdecoxib) is joined to node C and within supercluster having 18, 20, 25, 24, 12, 28,
26, 27, 23, 21, 22, 19, and 8. Valdecoxib (drug 18) was found to be extremely close to
drug 28 in similarity, both having two aromatic rings, one sulfonamide group, one methyl
(-CH3) substituent, and one heterocyclic ring.

Fig. (3). Hierarchical cluster analysis by Euclidean distance and single linkage cluster rules. Beginning at
origin node A the 28 compounds presented in Table 3 and Table 4 are grouped according to highest level
of similarity according to properties. Drug 1 (lumiracoxib) is bound to node B and within supercluster
having 1, 10, 16, 14, 15, 5, 7, 11, 4, 17, 9, 13, 6, and 2. Drug 18 (valdecoxib) is joined to node C and
within supercluster having 18, 20, 25, 24, 12, 28, 26, 27, 23, 21, 22, 19, and 8.

K-means analysis performs a non-hierarchical divisive cluster analysis on input data
and is distinguished from the more common hierarchical clustering techniques [23,24].
Restraining the analysis to two clusters only, the resolution of drugs shown in (Figs. 1
and 2) into two groups for highest similarity closely resembles hierarchical cluster
analysis (see Fig. 3). The clusters are determined as follows: cluster 1) drug 1
(lumiracoxib), 2, 3, 4, 5, 6, 7, 9, 10, 11, 13, 14, 15, 16, and 17; cluster 2) 18
(valdecoxib), 8, 12, 19, 20, 21, 22, 23, 24, 25, 26, 27, and 28.
The properties of polar surface area and molecular weight for all analogs and drugs of
Table 3 and 4 are highly consistent and concordant in variation demonstrable in a 95%
ellipses (see Fig. 4). Note that all 28 compounds of Table 3 and 4 are contained with a
95% ellipses. If an actual value of the parameter lies outside the 95% confidence
interval, the parameter has a probability of 5% (or less) of happening by chance.
The purpose of multiple regression analysis is to predict a single variable from one or
more independent variables and learn more about the relationship between
independent or predictor variables [22]. The prediction of lumiracoxib analogous
compounds (see Table 3) values of formula weight (FW), these from Log P, PSA,

number of atoms (nAtoms), MV, number of rotatable bonds (nRotB), number of
oxygennitrogen (nON), and number of hydroxyl-amine groups (nOHNHn) is defined as
follows: FW= -22.57 + (4.750) (Log P)- (1.059)(PSA) + (21.248)(nAtoms) +
(12.360)(nON) + (5.635)(nOHNHn)- (0.454)(nRotB) + (0.4957)(MV). This model
explains 96.74% of the variance within the model and has a R2 of 0.9674. Similarly, the
prediction of valdecoxib analogous compounds (see Table 4) using formula weight
(FW), Log P, PSA, MV, nRotB, (nON), and (nOHNHn) for appears as follows: FW =
156.47 + (13.308)(Log P) + (0.2402) (PSA) + (5.335)(nON) + (2.184)(nOHNHn) –
(0.2935)(nRotB) + (0.2668)(MV). This model explains 56.05% of the variance within the
model and has a R2 of 0.5605. By using these numerical models it is possible to predict
additional compounds based on scaffolding for lumiracoxib and valdecoxib.

Fig. (4). 95% Ellipses plot. The relationship of molecular weight (independent variable) to polar surface
area (dependent variable) shows that all drugs found in Table 3 and Table 4 fall within the 95% ellipses
confidence interval. The ellipses is the region containing 95% of the uncertainty. The in silico search
results are consistent when considering molecular weight and polar surface area.

Further comparison of analogs to their parent compounds is achieved by determination
of drug likeness scores for kinase inhibitor, protease inhibitor, and general enzyme
inhibitor. Effective and useful scores for drug likeness of these categories determined by
Molinspiration cheminformatics (see Materials and Methods) for kinase inhibitor fall
within - 1.50 to 0.50 (90% confidence interval), protease inhibitor is - 1.50 to 0.4 (90%
confidence interval), and enzyme inhibitor is -1.00 to 0.4 (90% confidence interval).
Drug likeness scores of analogs are presented in Table 7 with all analogs falling well
within the range of 90% confidence interval for kinase inhibitor, protease inhibitor, and
general enzyme inhibitor. These results solidify the considerable potential for these
analogs to perform as inhibitors of the COX-2 enzyme.

DISCUSSION
Previous studies have shown the COX-2 isozyme appears to play a role in a number of
pathways to cancer and is induced by oncogenes and over expressed in premalignant
and malignant tumors [25]. The COX-2 enzyme is known to be over expressed in
numerous cancers such as [25]: gastric cancer, Barrett's esophagus, hepatocellular
cancer, pancreatic malignancies, oral leukoplakia, head and neck cancer, nonsmall cell
lung cancer, breast, prostate, bladder cancers, and colorectal carcinomas [26]. Because
overexpression of COX2 inhibits apoptosis and allows cancer to grow, it is possible that
COX-2 inhibitors can help ensure that cancer cells die and help target the earliest
stages of carcinogenesis [25]. Consequently the search and design for new COX-2
inhibitors should have an immense benefit for many cancer patients.
Advances in chemo-informatics allow categorizing and screening by overall
physicochemical properties of potential drug candidates based entirely on their
molecular structures [27]. Studies have shown that drug candidates having PSA > 140
A2 are poorly absorbed and an increase of PSA decreases membrane permeability
[27]. Other criteria of properties to enable good drug absorption are the Rule of 5 that
states poor drug permeation is more likely with the following parameters [28]: 1)
Molecular weight is over 500; 2) Log P is over 5; 3) More than 10 hydrogen bond
accepters (nitrogen and oxygen atoms); 4) More than 5 hydrogen bond donors
(hydroxyl and amine groups). These criteria will assist the examination of the 26 novel
COX-2 inhibitors presented in this study.

The structure of lumiracoxib (see Fig. 1) differs from other COX-2 inhibitors, it is an
analogue of diclofenac, has one chlorine substituted by fluorine and the phenylacetic
acid has a methyl group in meta position which makes it a member of the arylalkanoic
acid class of NSAIDs. Lumiracoxib has the highest COX-2 selectivity of any NSAID [29].
The 16 lumiracoxib analogous compounds have pharmaceutical properties inherent to
COX-2 inhibitors (see Fig. 1). Substituents common to all 17 drugs and establish criteria
are: 1) Two aromatic rings; 2) At least two oxygen atoms; 3) At least one carboxyl
group. Other atoms present but not general are halogen atoms, nitrogen atoms, and
amide groups.
The success rate for in silico identification of lumiracoxib analogs was less than 16%.
The 10 valdecoxib analogous compounds have pharmaceutical properties inherent to
COX-2 inhibitors (see Fig. 2). Characteristic common to all 11 drugs are: 1) Two
aromatic rings; 2) At least two oxygen atoms; 3) At least one sulfonamide group. Other
atoms present but not general are chlorine atom, oxadiazole substituent, and
benzimidazole groups. The success rate for in silico identification of valdecoxib analogs
was less than 10%.
The variation of substituents will affect molecular properties of these analogs and allow
comparison to those of known specific COX-2 inhibitors presented in Table 1 [21] and
with summary statistics of Table 1 shown in Table 2 [21]. Comparing the maximum and
minimum bounds of known COX-2 inhibitors (see Tables 1 and 2) to properties of
lumiracoxib and valdecoxib based analogs (see Table 3 and Table 4) and their
summary statistics (see Table 5 and Table 6), essentially all pertinent pharmaceutical
descriptors fall within range. Those properties within numerical range of known COX-2
inhibitors include: number of oxygen atoms, nitrogen atoms, hydroxyl groups, amine
groups; number of rotatable bonds, Log P, polar surface area, Rule of 5, and molecular
volume (in the case of valdecoxib analogs).
Polar surface area of drug candidates have been shown to be indicative of the potential
extent of intestinal absorption following oral administration [30]. Thusly set parameters
can predict the expected level of intestinal absorption, which for lumiracoxib and
valdecoxib analogs would be greater than 40% of drug present. Cluster analysis is a
tool for exploratory data mining and a common technique for statistical data analysis
[23,24]. Identifying groups of individuals or objects that are similar to each other but
different from individuals in other groups can potentially resolve divergent clinical
activities among alike drug categories. The vertical agglomerative dendrogram shown in
(Fig. 3) differentiates lumiracoxib (drug 1) which joins at node B from valdecoxib (drug
18) which joins at node C. Rigorously considered the COX-2 inhibitor lumiracoxib is
distinct from but most similar to drugs 10, 16, 14, 15, 5, 7, 11, 4, 17, 9, 13, 6, and 2.
Likewise, the drug valdecoxib (drug 18) at highest resolution is highest alike to drug 28
but similar to drugs 20, 25, 24, 12, 26, 27, 23, 21, 22, 19, and 8. Drug 3 is joined to all
other analogs at node A and counted distinct from other drugs.

Confidence Intervals for a population indicates a range of values that contains the
estimated parameter a high proportion of the time [24]. It relates how stable an estimate
is since a stable estimate is one that would be close to the same value if the survey
were repeated. The 95% confidence interval is constructed so that 95% of such
intervals will contain the parameter. A 95% ellipses outcome means that if this same
population is sampled the resulting intervals would bracket the true population of values
in 95% of the cases. The 95% ellipses shown in (Fig. 4) contains all 28 drugs of Table 3
and Table 4 that clearly indicates the in silico search produced drugs having very high
consistency in descriptors of polar surface area and molecular weight.
Path analysis is closely related to multiple regression. This techniques allows the testing
of theoretical propositions about cause and effect without manipulating variables. The
causal modeling requires an assumption of the model rather than a property of the

output or consequence of the technique. Path coefficients provide estimates of the
magnitude and significance of hypothesized causal connections between sets of
properties. Considering properties of known COX-2 selective inhibitors (see Table 1) the
path coefficients for determination of formula weight are very high for Log P (0.824),
number of atoms (2.024), and number of oxygen & nitrogen atoms (1.616). Path
analysis of Table 3 and Table 4 likewise showed very high path coefficient for number of
atoms (0.863) and significant outcome for number of oxygen & nitrogen atoms (0.131),
and Log P (0.231) in expression of formula weight. Emphasizing the importance of
these properties for expression of formula weight and putatively for the design of novel
effective COX-2 selective inhibitors.
Comparing COX-2 inhibitors of Table 1 to drugs of Table 3 and Table 4 by one- way
ANOVA shows the means of properties Log P, polar surface area, and rotatable bonds
are the same (P = 0.09866). In addition, all Log P and polar surface area values in
Table 1, Table 3, and Table 4 are from identical populations based on results of
Kruskal-Wallis test (P = 0.172 and P = 0.989, respectively). Therefore the analog drugs
are found to be consistent and highly similar to previous known selective COX-2
inhibitors.
Comparison by unpaired t-test for Log P and polar surface area (two properties
important for determination of membrane permeation [28]) of COX-2 inhibitors of Table
1 to all drugs in Table 3 and 4 indicate no difference among the groups (two-tailed P =
0.3543 and P = 0.8805, respectively). Therefore the analog drugs are found to be
consistent and highly similar to previous known selective COX-2 inhibitors.
Cluster analysis aided resolution of novel drug designs for similarity using determined
molecular properties has been shown to be effective distinguishing efficacious
substituent substitution [31]. Therefore this study has shown that in silico substituent
search via data library with numerical analysis, to include cluster analysis, can identify
underlying relationships of analogous drug scaffolds and assist in identifying optimal
substituent replacement for optimizing drug activity.
Drug likeness is characterized by various molecular properties and structure features
which determine whether a molecule is similar to the known drugs. Molinspiration
Chemoinformatics utilizes Bayesian statistics for comparing structures of active ligands
with structures of inactive molecules in an effort to identify substructure features typical
for active molecules. Because kinase inhibitors can be associated with the inflammatory
mechanism [32], the determination of kinase inhibition scores assists the evaluation of
these analogs. All analogs are also compared to protease inhibitors and general
enzyme inhibitors since these compounds can have medicinal application [33].
Calculated drug likeness scores for all drugs are shown in Table 7 with values
determined for every analog falling within the 90% confidence interval for potent drug
likeness in the categories of kinase, protease, and general enzyme inhibitors. These
results further substantiates their substantial potential for inhibition of COX-2 enzyme.
The Grubbs' test for numerical outliers, indicated no outliers among the drug likeness

scores for all compounds in the cases of kinase, protease, or general enzyme inhibitors.
All analogs are drug-like and comparable to known medicinal compounds lumiracoxib or
valdecoxib.
For analogs of lumiracoxib (see Fig. 1) the substituents of amines, hydroxyl groups,
carbonyl oxygens, and carboxyl groups remain polar as in the parent drug. Aromatic
rings remain non-polar and with similar action as in the parent compound. For analogs
of valdecoxib (see Fig. 2) the substituents of amines and sulfonamide remain polar as in
the parent drug. Aromatic rings and methyl groups remain nonpolar and with similar
action as in the parent compound. Examination of the structures for placement of polar
groups (such as –NHn or -OH) relative to that of parent compounds show comparable
placement of these moieties useful for binding and docking. In addition the molecular
volumes (see Table 3 and 4) of analogs are statistically consistent to that of parent
compounds. Altogether the drug likeness scores and physicochemical properties (i.e.
molecular volume) indicates considerable likelihood for effective inhibitors of the COX-2
enzyme.

CONCLUSIONS
The beneficial medicinal action of COX-2 inhibitors affirms further study and
development of new drug designs. In this study a total of 26 novel drug scaffolds
focusing on COX-2 selective inhibition have been presented. These analogs of
lumiracoxib and valdecoxib have molecular properties consistent with those of known
specific COX-2 selective inhibitors. Following in silico search for substituent substitution
a set of analogs were identified and provided criteria for structural features inherent for
COX-2 inhibitors. For lumiracoxib set analogs, parameters required: 1) Two aromatic
rings; 2) At least two oxygen atoms; 3) At least one carboxyl group. For valdecoxib
analogous compounds (sulfonamide based) required pharmaceutical properties are: 1)
Two aromatic rings; 2) At least two oxygen atoms; 3) At least one sulfonamide group.
Valdecoxib analogs may include but not required multiple methyl (-CH3) substituents,
halogen atoms, and heterocyclic ring. The success rate for the in silico search outcome
was less than 16% and less than 10% for lumiracoxib and valdecoxib analogs,
respectively.
K-means cluster analysis indicated that drug 1 (lumiracoxib) is most similar to drugs 2,
3, 4, 5, 6, 7, 9, 10, 11, 13, 14, 15, 16, and 17 with drug 18 (valdecoxib), most similar to
8, 12, 19, 20, 21, 22, 23, 24, 25, 26, 27, and 28. Path analysis identified Log P, number
of atoms, oxygens, and nitrogens to most influence formula weight of known COX-2
inhibitors. The unpaired t-test indicated that Log P and polar surface area of known
COX-2 selective inhibitors is no different from those of 26 drug analogs presented here.
A multiple regression model using vital drug-likenss properties will aid in the predicting
additional analogs. The further search for novel COX-2 inhibitors is highly advisable due
to their beneficial medicinal action. In silico optimization for substituent substitution is
shown here to provide an effective tool in that regard.
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ABBREVIATIONS
PSA = Polar surface area
FW = Formula weight
NO = Nitrogen and oxygen atoms
OH = Hydroxyl group
NHn = Amine group
COX-2 = Cyclooxygenase-II enzyme
NSAIDs = Non-steroidal anti-inflammatory drugs
MV = Molecular volume
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